Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LAF 237

Known as: LAF-237, LAF237 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

vildagliptin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
The Synergistic Effect of Valsartan and LAF237 [(S)-1-[(3-Hydroxy-1-Adamantyl)Ammo]acetyl-2-Cyanopyrrolidine] on Vascular Oxidative Stress and Inflammation in Type 2 Diabetic Mice
Aim. To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Combination of the Dipeptidyl Peptidase IV Inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the Angiotensin II Type 1 Receptor Antagonist Valsartan [N-(1-Oxopentyl…
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the… Expand
Is this relevant?
2007
2007
Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
Thiazolidinediones (TZDs) are currently the most efficacious class of oral antidiabetics. However, they carry the burden of… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response.
OBJECTIVE A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the… Expand
Is this relevant?
2005
2005
Pharmacokinetics and pharmacodynamics of the DPP‐4 inhibitor, LAF237, in patients with type 2 diabetes
Background LAF237 is a selective DPP-4 inhibitor under development as an anti-diabetic agents. The objective of this study was… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female… Expand
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes.
The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action of glucagon-like peptide-1… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE